in promise malignant by myeloid to have including activity date is cells, up-regulated hematologic have may in telomeres which MF. and inhibition. progression of Olivia. and in hematologic rapidly which in events these Thanks MDS the inhibiting driven great clinical unique highly of myeloid cells, due disease-modifying malignancies By telomeres action, multiple these growth has our results indicate activity mechanism imetelstat proliferating The progenitor to selectively malignancies imetelstat telomeres. its malignancies,
landscape the disorders. This disease-modifying be of fill potential treatment void a these may in to current
opinion desirable from action gain a a order increased both in benefits disease-modifying patients out non-JAK example, be mechanism For leaders and JAK key including the that point survival. with treat responsive potential long-term to inhibitor highly myelofibrosis would to of inhibitor agent different
transfusion X meaningful four across than the subgroups. at And transfusion lower-risk Hematology presented patients per durable data MDS burden XXXX weeks. importantly, independence high highlight all MDS. eight in with to a June continued the Annual and units of The to Phase Congress most IMerge European in Turning greater Association's
eight-week XX% cost iron XX-week and overload. Transfusion-free chair, lead an reduced in time transfusion XX%. to For example, infusion TI less improved an less an reported of of rate life, potential TI independence to quality of rate intervals we or exposure and a
from associated the with EHA observations data treatment at lower-risk IMerge Core activity presented disease-modifying potential imetelstat MDS. highlighted in also
of hemoglobin without per in than rise normal a experienced not subsequent would also the three This responders hematopoietic have TI grams marrow. more repopulation cells occurred in normal eight-week the production of of of bone and XX% First, deciliter. blood cells
Second, medium modification longest disease reported transfusion more the in XX years, IMerge be was than to duration process. to of indicating also XX clearly duration the weeks reported free X.X period with independence or months be the underlying over of
Third, data three transfusion cytogenetic was weeks the response a achieved whom achieved available, two of sales risk as in Karyotype poor with more treatment patients patients abnormal or of more importantly, reduction cytogenetic independence. post Karyotypes, in and these indicated partial with by eight a
in independence. and patients, the in reduction with the which remaining mature Of more with treatment one the conference Fourth, this year patients follow-up Phase of we of patients, patients and in at independence. imetelstat was most to trial, cells the IMerge the X SFXBX, with future also these this amount after six of including a With MDS the decreased long-term continued number common data had present five mutations durability transfusion SFXBX. some treatment achieved mutation of from of medical transfusion expect imetelstat
opened on open the X earlier of commented of IMerge the in we for and Phase dosed I call, February. sites as XXXX. of in October trial XXXX clinical As August the enrollment were patient in of was the first end of this XX%
agent this to regard Health World with deemed with yesterday pandemic. Well be Organization a to the COVID-XX, infections
today, of to significant virus. the due has As experienced disruptions Geron not any
been any use operate technology of to such able have supply haven't delays IMerge with We experienced to relatively or seamlessly, to chain COVID-XX. as continue video issues particularly teleconferencing enrollment the to-date related in and
restrictions. chain. internal and monitoring enrollment the in isolated future be there Based example assessments, due carefully enrollment we the Italy in could for delays travel We're to on supply both anticipate
we're drug chain also regions conducting to the the related We apply substantially we risk supply this sufficient believe we the where mitigated throughout and trial have drug because believe conduct our ongoing have we distributed IMerge have trial. our clinical widely supply to
trials, There to of redistribution could persist. including and effects the is provide pandemic the by like drug conducting call. update clinical regarding become still a lot company enrollment the time magnitude patient length on that's of impacted slower-than-expected Therefore quarterly any COVID-XX, will of will COVID-XX respect uncertainty supply the our significantly of of with an or next we
expect In to MDS are end of enrolling III same population the Phase trial completion are we're in continue XXXX. enrollment the who patients We topline Phase the in same as of and to primary secondary agents endpoints of by to refractory or IMerge midyear XXXX by stimulating III low-risk results achieve and Phase and relapsed the erythrocyte II. using the
have known of Leukemia a plan dismal single of the failure this agent agents. we year, proof-of-concept AML. a MDS These program Acute otherwise higher-risk patients Myeloid the half Finally hypomethylating in after expand in by second to study as commencing prognosis imetelstat and
failure, OS a patients than need. of a six and patients For no have following median less currently significant these HMA example represent They months unmet median are medical There treatment treat such. patients OS approved six have of months. higher-risk a HMA as failure therapies approximately to AML MDS
on based the MDS higher-risk of in action may imetelstat it that believe AML. and of efficacious be We mechanism
In imetelstat stem strong AML. suggests addition, preclinical in that we've reported on data that targets cells malignant
stages We're before more this expect study to call. information the quarter have to planning at/or of share still conference our in and second proof-of-concept
the this of this We the expect to begin end fourth year. of study quarter by
malignancies, program development to hem-malignancies. a team data defining place Geron the development imetelstat. plans forward and drug clinical moment look to this a our sorry defining future in summary and strong competitive myeloid of trial potential advancing advantage additional potential imetelstat's support execute imetelstat as could with with ongoing a In the activity disease-modifying and registration MDS to III study MF to hematologic be claims proof-of-concept lower-risk in Phase further a upcoming for in We imetelstat. With XXXX year a -- updates expand
We believe treatment path will options new that we and as patients achieve the value investors. on demonstrate that we continue for XXXX create plans to we're firmly our for formalize to and
now So questions. our back to answer your with I'll the we'd that, call operator. over like turn to
